Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York
MD Elliott Bennett-Guerrero, PhD Jamie L Romeiser, BS Lillian R Talbot, MD Tahmeena Ahmed, MD Linda J Mamone, MD Sunitha M Singh, PhD Janet C Hearing, MD Huda Salman, BS Dishaw D Holiprosad, BS Alex T Freedenberg, PhD Jason A Carter, BS Nicholas J Browne, PhD Megan E Cosgrove, BS Margaret E Shevik, BS Laura M Generale, BSN Margaret A Andrew, MD Sharon Nachman, MD Bettina C Fries
Critical Care Medicine, doi:10.1097/ccm.0000000000005066
OBJECTIVES: Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determine if administration of convalescent plasma to patients with coronavirus disease 2019 increases antibodies to severe acute respiratory syndrome coronavirus 2 and improves outcome. DESIGN: Double-blind randomized controlled trial. SETTING: Hospital in New York. PATIENTS: Patients with polymerase chain reaction documented coronavirus disease 2019 infection. INTERVENTIONS: Patients were randomized (4:1) to receive 2 U of convalescent plasma versus standard plasma. Antibodies to severe acute respiratory syndrome coronavirus 2 were measured in plasma units and in trial recipients.
MEASUREMENTS AND MAIN RESULTS: Enrollment was terminated after emergency use authorization was granted for convalescent plasma. Seventy-four patients were randomized. At baseline, mean (sd) Acute Physiology and Chronic Health Evaluation II score (23.4 [5.6] and 22.5 [6.6]), percent of patients intubated (19% and 20%), and median (interquartile range) days from symptom onset to randomization of 9 (6-18) and 9 (6-15), were similar in the convalescent plasma versus standard plasma arms, respectively. Convalescent plasma had high neutralizing activity (median [interquartile range] titer 1:526 [1:359-1:786]) and its administration increased antibodies to severe acute respiratory syndrome coronavirus 2 by 14.4%, whereas standard plasma administration led to an 8.6% decrease (p = 0.005). No difference was observed for ventilator-free days through 28 days (primary study endpoint): median (interquartile range) of 28 (2-28) versus 28 (0-28; p = 0.86) for the convalescent plasma and standard plasma groups, respectively. A greater than or equal to 2 point improvement in the World Health Organization scale was achieved by 20% of subjects in both arms (p = 0.99). All-cause mortality through 90 days was numerically lower in the convalescent plasma versus standard plasma groups (27% vs 33%; p = 0.63) but did not achieve statistical significance. A key prespecified subgroup analysis of time to death in patients who were intubated at baseline was statistically significant; however, sample size numbers were small. CONCLUSIONS: Administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection increased antibodies to severe acute respiratory syndrome coronavirus disease 2 but was not associated with improved outcome.
References
Agarwal, Mukherjee, Kumar, PLACID Trial Collaborators: Convalescent plasma in the management of moderate Covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Beigel, Aga, Mc, IRC005 Study Team: Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial, Lancet Respir Med
Brill, Daley, Gearwar, Generale, Halper et al., Stony Brook Medicine COVID Plasma Trial Group are as follows: Investigators: Elliott Bennett-Guerrero (Principal Investigator, Critical Care)
Carter, Freedenberg, Romeiser, Stony Brook Medicine COVID Plasma Trial Group: Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors, Transfusion
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A
Fernando, Seshan, Pham ; Lillian, Browne, Carter et al., Plaque Reduction Neutralization Assay: Janet Hearing. Regulatory (Investigational New Drug [IND] and Institutional Review Board [IRB] support)
Freedenberg, Pan, Diehl, Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial, Transfusion
Jin, Gu, Yuan, Treatment of six COVID-19 patients with convalescent plasma, medRxiv
Joyner, Bruno, Klassen, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc
Joyner, Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 protocol
Joyner, Senefeld, Klassen, US EAP COVID-19 Plasma Consortium: Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial threemonth experience, medRxiv
Joyner, Wright, Fairweather, Early safety indicators of COVID-19 convalescent plasma in 5000 patients, J Clin Invest
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial, JAMA
Libster, Marc, Wappner, Fundación INFANT-COVID-19 Group: Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med
Liu, Lin, Baine, Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study, Nat Med
Mair-Jenkins, Saavedra-Campos, Baillie, Convalescent Plasma Study Group: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis, J Infect Dis
Marano, Vaglio, Pupella, Convalescent plasma: New evidence for an old therapeutic tool?, Blood Transfus
Rogers, Shehadeh, Mylona, Convalescent plasma for patients with severe COVID-19: A matched cohort study, Clin Infect Dis
Salazar, Christensen, Graviss, Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Salazar, Perez, Ashraf, Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma, Am J Pathol
Sanders, Monogue, Jodlowski, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review, JAMA
Shen, Wang, Zhao, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA
Simonovich, Pratx, Scibona, PlasmAr Study Group: A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med
Ye, Fu, Ren, Treatment with convalescent plasma for COVID-19 patients in Wuhan, China, J Med Virol
{ 'indexed': { 'date-parts': [[2022, 12, 21]],
'date-time': '2022-12-21T02:36:13Z',
'timestamp': 1671590173033},
'reference-count': 22,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2021, 4, 16]]},
'DOI': '10.1097/ccm.0000000000005066',
'type': 'journal-article',
'created': {'date-parts': [[2021, 4, 20]], 'date-time': '2021-04-20T03:19:51Z', 'timestamp': 1618888791000},
'source': 'Crossref',
'is-referenced-by-count': 31,
'title': 'Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in '
'Coronavirus Disease 2019 Infected Hospitalized Patients in New York',
'prefix': '10.1097',
'volume': 'Publish Ahead of Print',
'author': [ {'given': 'Elliott', 'family': 'Bennett-Guerrero', 'sequence': 'first', 'affiliation': []},
{'given': 'Jamie L.', 'family': 'Romeiser', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lillian R.', 'family': 'Talbot', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tahmeena', 'family': 'Ahmed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Linda J.', 'family': 'Mamone', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sunitha M.', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Janet C.', 'family': 'Hearing', 'sequence': 'additional', 'affiliation': []},
{'given': 'Huda', 'family': 'Salman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dishaw D.', 'family': 'Holiprosad', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alex T.', 'family': 'Freedenberg', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jason A.', 'family': 'Carter', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nicholas J.', 'family': 'Browne', 'sequence': 'additional', 'affiliation': []},
{'given': 'Megan E.', 'family': 'Cosgrove', 'sequence': 'additional', 'affiliation': []},
{'given': 'Margaret E.', 'family': 'Shevik', 'sequence': 'additional', 'affiliation': []},
{'given': 'Laura M.', 'family': 'Generale', 'sequence': 'additional', 'affiliation': []},
{'given': 'Margaret A.', 'family': 'Andrew', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sharon', 'family': 'Nachman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bettina C.', 'family': 'Fries', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'reference': [ { 'key': 'R1-20210618',
'doi-asserted-by': 'crossref',
'first-page': '533',
'DOI': '10.1016/S1473-3099(20)30120-1',
'article-title': 'An interactive web-based dashboard to track COVID-19 in real time.',
'volume': '20',
'author': 'Dong',
'year': '2020',
'journal-title': 'Lancet Infect Dis'},
{ 'key': 'R2-20210618',
'first-page': '1824',
'article-title': 'Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A '
'review.',
'volume': '323',
'author': 'Sanders',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'R3-20210618',
'doi-asserted-by': 'crossref',
'first-page': '80',
'DOI': '10.1093/infdis/jiu396',
'article-title': 'The effectiveness of convalescent plasma and hyperimmune immunoglobulin '
'for the treatment of severe acute respiratory infections of viral '
'etiology: A systematic review and exploratory meta-analysis.',
'volume': '211',
'author': 'Mair-Jenkins',
'year': '2015',
'journal-title': 'J Infect Dis'},
{ 'key': 'R4-20210618',
'first-page': '152',
'article-title': 'Convalescent plasma: New evidence for an old therapeutic tool?',
'volume': '14',
'author': 'Marano',
'year': '2016',
'journal-title': 'Blood Transfus'},
{ 'key': 'R5-20210618',
'doi-asserted-by': 'crossref',
'first-page': '9490',
'DOI': '10.1073/pnas.2004168117',
'article-title': 'Effectiveness of convalescent plasma therapy in severe COVID-19 '
'patients.',
'volume': '117',
'author': 'Duan',
'year': '2020',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'key': 'R6-20210618',
'article-title': 'Treatment of six COVID-19 patients with convalescent plasma.',
'author': 'Jin',
'journal-title': 'medRxiv'},
{ 'key': 'R7-20210618',
'doi-asserted-by': 'crossref',
'first-page': '1680',
'DOI': '10.1016/j.ajpath.2020.05.014',
'article-title': 'Treatment of coronavirus disease 2019 (COVID-19) patients with '
'convalescent plasma.',
'volume': '190',
'author': 'Salazar',
'year': '2020',
'journal-title': 'Am J Pathol'},
{ 'key': 'R8-20210618',
'doi-asserted-by': 'crossref',
'first-page': '1582',
'DOI': '10.1001/jama.2020.4783',
'article-title': 'Treatment of 5 critically ill patients with COVID-19 with convalescent '
'plasma.',
'volume': '323',
'author': 'Shen',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'R9-20210618',
'doi-asserted-by': 'crossref',
'first-page': '1890',
'DOI': '10.1002/jmv.25882',
'article-title': 'Treatment with convalescent plasma for COVID-19 patients in Wuhan, '
'China.',
'volume': '92',
'author': 'Ye',
'year': '2020',
'journal-title': 'J Med Virol'},
{ 'key': 'R10-20210618',
'doi-asserted-by': 'crossref',
'first-page': '1708',
'DOI': '10.1038/s41591-020-1088-9',
'article-title': 'Convalescent plasma treatment of severe COVID-19: A propensity '
'score-matched control study.',
'volume': '26',
'author': 'Liu',
'year': '2020',
'journal-title': 'Nat Med'},
{ 'key': 'R11-20210618',
'article-title': 'Convalescent plasma for patients with severe COVID-19: A matched cohort '
'study.',
'author': 'Rogers',
'year': '2020 Oct 10',
'journal-title': 'Clin Infect Dis'},
{ 'key': 'R12-20210618',
'doi-asserted-by': 'crossref',
'first-page': '2290',
'DOI': '10.1016/j.ajpath.2020.08.001',
'article-title': 'Treatment of COVID-19 patients with convalescent plasma reveals a '
'signal of significantly decreased mortality.',
'volume': '190',
'author': 'Salazar',
'year': '2020',
'journal-title': 'Am J Pathol'},
{ 'key': 'R14-20210618',
'doi-asserted-by': 'crossref',
'first-page': '4791',
'DOI': '10.1172/JCI140200',
'article-title': 'Early safety indicators of COVID-19 convalescent plasma in 5000 '
'patients.',
'volume': '130',
'author': 'Joyner',
'year': '2020',
'journal-title': 'J Clin Invest'},
{ 'key': 'R15-20210618',
'doi-asserted-by': 'crossref',
'first-page': '1888',
'DOI': '10.1016/j.mayocp.2020.06.028',
'article-title': 'Safety update: COVID-19 convalescent plasma in 20,000 hospitalized '
'patients.',
'volume': '95',
'author': 'Joyner',
'year': '2020',
'journal-title': 'Mayo Clin Proc'},
{ 'key': 'R16-20210618',
'article-title': 'Effect of convalescent plasma on mortality among hospitalized patients '
'with COVID-19: Initial three-month experience.',
'author': 'Joyner',
'journal-title': 'medRxiv'},
{ 'key': 'R18-20210618',
'doi-asserted-by': 'crossref',
'first-page': 'm3939',
'DOI': '10.1136/bmj.m3939',
'article-title': 'Convalescent plasma in the management of moderate Covid-19 in adults in '
'India: Open label phase II multicentre randomised controlled trial '
'(PLACID Trial).',
'volume': '371',
'author': 'Agarwal',
'year': '2020',
'journal-title': 'BMJ'},
{ 'key': 'R19-20210618',
'doi-asserted-by': 'crossref',
'first-page': '460',
'DOI': '10.1001/jama.2020.10044',
'article-title': 'Effect of convalescent plasma therapy on time to clinical improvement '
'in patients with severe and life-threatening COVID-19: A randomized '
'clinical trial.',
'volume': '324',
'author': 'Li',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'R20-20210618',
'doi-asserted-by': 'crossref',
'first-page': '619',
'DOI': '10.1056/NEJMoa2031304',
'article-title': 'A randomized trial of convalescent plasma in COVID-19 severe pneumonia.',
'volume': '384',
'author': 'Simonovich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'R21-20210618',
'doi-asserted-by': 'crossref',
'first-page': '610',
'DOI': '10.1056/NEJMoa2033700',
'article-title': 'Early high-titer plasma therapy to prevent severe COVID-19 in older '
'adults.',
'volume': '384',
'author': 'Libster',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'R22-20210618',
'doi-asserted-by': 'crossref',
'article-title': 'Impact of serological and PCR testing requirements on the selection of '
'COVID-19 convalescent plasma donors.',
'author': 'Carter',
'year': '2021 Feb 8',
'journal-title': 'Transfusion',
'DOI': '10.1111/trf.16293'},
{ 'key': 'R23-20210618',
'doi-asserted-by': 'crossref',
'article-title': 'Neutralizing activity to SARS-CoV-2 of convalescent and control plasma '
'used in a randomized controlled trial.',
'author': 'Freedenberg',
'year': '2021 Jan 15',
'journal-title': 'Transfusion',
'DOI': '10.1111/trf.16283'},
{ 'key': 'R24-20210618',
'doi-asserted-by': 'crossref',
'first-page': '941',
'DOI': '10.1016/S2213-2600(19)30199-7',
'article-title': 'Anti-influenza immune plasma for the treatment of patients with severe '
'influenza A: A randomised, double-blind, phase 3 trial.',
'volume': '7',
'author': 'Beigel',
'year': '2019',
'journal-title': 'Lancet Respir Med'}],
'container-title': 'Critical Care Medicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.lww.com/10.1097/CCM.0000000000005066',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 6, 21]],
'date-time': '2021-06-21T06:00:29Z',
'timestamp': 1624255229000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/CCM.0000000000005066'}},
'subtitle': ['A Double-Blind Randomized Trial'],
'short-title': [],
'issued': {'date-parts': [[2021, 4, 16]]},
'references-count': 22,
'URL': 'http://dx.doi.org/10.1097/CCM.0000000000005066',
'relation': {},
'ISSN': ['0090-3493'],
'subject': ['Critical Care and Intensive Care Medicine'],
'published': {'date-parts': [[2021, 4, 16]]}}
